CanSino Biologics 

$3.86
6
-$0.11-2.77% Monday 20:00

Statistics

Day High
4.1
Day Low
3.97
52W High
6.99
52W Low
3.2
Volume
1,200
Avg. Volume
33
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Aug 22
$0.12
Aug 22
$0.12
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

23AprExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.05
-0.02
0.01
0.04
Expected EPS
N/A
Actual EPS
N/A

Financials

-45.96%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
226.26MRevenue
-103.98MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CASBF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Show more...
CEO
Dr. Xuefeng Yu Ph.D.
Employees
1105
Country
CN
ISIN
CNE100003F01

Listings

0 Comments

Share your thoughts

FAQ

What is CanSino Biologics stock price today?
The current price of CASBF is $3.86 USD — it has decreased by -2.77% in the past 24 hours. Watch CanSino Biologics stock price performance more closely on the chart.
What is CanSino Biologics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange CanSino Biologics stocks are traded under the ticker CASBF.
Is CanSino Biologics stock price growing?
CASBF stock has risen by +0% compared to the previous week, the month change is a -9.34% fall, over the last year CanSino Biologics has showed a -16.09% decrease.
When is the next CanSino Biologics earnings date?
CanSino Biologics is going to release the next earnings report on April 23, 2026.
What is CanSino Biologics revenue for the last year?
CanSino Biologics revenue for the last year amounts to 226.26M USD.
What is CanSino Biologics net income for the last year?
CASBF net income for the last year is -103.98M USD.
Does CanSino Biologics pay dividends?
Yes, CASBF dividends are paid annual. The last dividend per share was 0.12 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does CanSino Biologics have?
As of April 01, 2026, the company has 1,105 employees.
In which sector is CanSino Biologics located?
CanSino Biologics operates in the Health Care sector.
When did CanSino Biologics complete a stock split?
CanSino Biologics has not had any recent stock splits.
Where is CanSino Biologics headquartered?
CanSino Biologics is headquartered in Tianjin, CN.